Elisabeth Stubsrud

Title: Elisabeth Stubsrud: Innovator in Anticancer Vaccine Development

Introduction

Elisabeth Stubsrud is a prominent inventor based in Oslo, Norway. She has made significant contributions to the field of cancer treatment through her innovative work on therapeutic vaccines. Her dedication to advancing medical science is evident in her patented invention.

Latest Patents

Elisabeth holds a patent for a therapeutic anticancer neoepitope vaccine. This invention relates to an anticancer vaccine that includes polynucleotides or polypeptides, methods of treating cancer, and methods for producing the vaccine. The vaccine comprises a polynucleotide with a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker, and an antigenic unit. The antigenic unit consists of 3 to 50 antigenic subunits separated by a second linker, with each subunit containing a part of a cancer neoepitope sequence. The vaccine can also include a polypeptide encoded by the polynucleotide or a dimeric protein with two polypeptides encoded by the polynucleotide. This innovative approach has the potential to enhance cancer treatment options.

Career Highlights

Elisabeth is currently associated with Nykode Therapeutics ASA, where she continues to work on groundbreaking research in the field of immunotherapy. Her expertise and innovative mindset have positioned her as a key player in the development of novel therapeutic solutions.

Collaborations

Elisabeth collaborates with talented professionals in her field, including Stine Granum and Agnete Brunsvik Fredriksen. These collaborations foster a dynamic environment for innovation and research.

Conclusion

Elisabeth Stubsrud's contributions to the development of anticancer vaccines highlight her commitment to improving cancer treatment. Her innovative work and collaborations are paving the way for advancements in medical science.